S&P 500
3,351.28+2.12(+0.06%)Nasdaq
11,010.98-97.12(-0.87%)Russell 2000
1,569.18+24.56(+1.59%)
American Express Company (AXP)
Chart Events
Performance Outlook
| Previous Close | 95.92 |
| Open | 95.29 |
| Bid | 99.02 x 800 |
| Ask | 99.06 x 1000 |
| Day's Range | 94.95 - 99.30 |
| 52 Week Range | 67.00 - 138.13 |
| Volume | 4,690,730 |
| Avg. Volume | 5,465,798 |
| Market Cap | 79.84B |
| Beta (5Y Monthly) | 1.08 |
| PE Ratio (TTM) | 20.39 |
| EPS (TTM) | 4.86 |
| Earnings Date | Oct 16, 2020 - Oct 20, 2020 |
| Forward Dividend & Yield | 1.72 (1.79%) |
| Ex-Dividend Date | Jul 01, 2020 |
| 1y Target Est | 104.60 |
- GlobeNewswire
QuestCap to Host Corporate Update Webinar on Investments in Glenco Medical, Amino Therapeutics and Spectral Analytics
Investor Webinar to be held Monday, August 10th at 10 am Eastern TimeNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Social-impact investment company QuestCap Inc. (CSE:QSC; FRA:34C1) is pleased to host a corporate webinar to provide updates and developments from investment partners.QuestCap’s recent investments include: * Glenco Medical Corp. is a medical treatment company that specializes in extended clinical care, home treatment and innovative performance technologies using wearable, unrestricted and individual therapies to accelerate orthopaedic injury healing and training recovery. Glenco Medical develops and organizes data driven COVID-19 screening protocols and testing procedures. As virus testing is crucial for recovery, these protocols are designed to provide a safe return for business operations, manufacturing, hydropower plants, service sectors, sports, technology industries etc. using up to date local public health recommendations and guidelines. * Amino Therapeutics is currently focused on developing biologic therapeutics for COVID-19. Amino’s research targets small molecule drug candidates and targeted drug delivery systems to transport biologics into the cytosol. * Spectral Analytics received Institutional Review Board (IRB) approval for the clinical study and is the Principal Investigator for the Phase 1 study. Spectral is testing the efficacy of the combination of two FDA approved drugs to treat COVID 19.“We’ve been very focused on putting our capital to work in projects that show promise in mitigating the spread of the virus while indicating an opportunity to deliver strong financial results,” said Doug Sommerville, CEO of QuestCap. “We’ve leveraged the specialized knowledge of our Global Advisory Team to help identify, connect with, and guide our investments into these high-potential projects as well as new opportunities post COVID19. We’re very pleased with the progress we are seeing.” QuestCap Corporate Update Webinar QuestCap is hosting a Corporate Update webinar on Monday, August 10 at 10 am Eastern time that will give the Company’s investment partners the opportunity to provide an update on their work. Select representatives will make short presentations on their progress. Registration Link https://us02web.zoom.us/webinar/register/WN_nZtjhxAvSbej0hB06tbKRQ About QuestCap Inc. QuestCap Inc. (CSE:QSC; FRA:34C1) is a social-impact investment company. It seeks, secures and funds recognized sciences, technologies, and solutions that impact our global community today.The QuestCap executive team is complemented by a panel of global advisors that provide expertise across industries and geographies. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopedic treatment, foot and ankle care, and sports medicine.QuestCap provides financing for a diverse range of entities in exchange for pre-determined royalties or distributions, or acquires all or part of one or more businesses, portfolios or other assets.For additional information, please contact: Doug Sommerville, CEO Doug.Sommerville@Questcapinc.com 416-301-5418For US media enquires please contact: Veronica Welch veronica@vewprmedia.com +1-508-643-8000Cautionary Note Regarding Forward-looking InformationThis press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the use of the corporate update; the pursuit by QuestCap of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
- Benzinga
Analyzing American Express's Unusual Options Activity
On Thursday, shares of American Express (NYSE: AXP) saw unusual options activity. After the option alert, the stock price moved down to $95.09. * Sentiment: BULLISH * Option Type: SWEEP * Trade Type: CALL * Expiration Date: 2020-08-07 * Strike Price: $94.00 * Volume: 741 * Open Interest: 3233 Signs of Unusual Options Activity One way options activity can be considered unusual is when volume is exceptionally high. The volume of options activity refers to the number of shares contracts traded for a day. Unsettled contracts that have been traded, but not yet closed, are called open interest. These contracts are not closed because a buyer has not purchased a contract, or a seller has not sold it.A contract with an expiration date in the distant future is another tell of unusual activity. Generally, additional time until a contract expires increases the potential for it to reach its strike price and grow its time value. Time value is important in this context because it represents the difference between the strike price and the value of the underlying asset.Contracts with a strike price far from the underlying price are also considered unusual because they are defined as being "out of the money". This occurs when the underlying price is under the strike price on a call option, or above the strike price on a put option. These trades are made because the underlying asset value is expected to change dramatically in the future, and the buyer or seller can take advantage of a greater profit margin.Understanding Sentiment Options are "bullish" when a call is purchased at/near ask price or a put is sold at/near bid price. Options are "bearish" when a call is sold at/near bid price or a put is bought at/near ask price.These observations are made without knowing the investor's true intent by purchasing these options contracts. The activity is suggestive of these strategies, but an observer cannot be sure if a bettor is playing the contract outright or if the options bettor is hedging a large underlying position in common stock. For the latter case, bullish options activity may be less meaningful than the exposure a large investor has on their short position in common stock.Using These Strategies to Trade Options Unusual options activity is an advantageous strategy that may greatly reward an investor if they are highly skilled, but for the less experienced trader, it should remain as another tool to make an educated investment decision while taking other observations into account.For more information to understand options alerts, visit https://pro.benzinga.help/en/articles/1769505-how-do-i-understand-options-alertsSee more from Benzinga * Looking Into American Express's Return On Capital Employed * Price Over Earnings Overview: American Express * Recap: American Express Q2 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- GlobeNewswire
Discovery Channel's Shark Week Special Featuring Mike Tyson Implements Glenco’s protocol “Standard for Safe Sets”
Lionsgate’s division, Pilgrim Media Group, implements the Glenco’s protocol for optimal health and safety during filming of Mike Tyson special Investor Webinar to be held Monday, August 10th at 10 am Eastern Time NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- QuestCap Inc. (“QuestCap” or the “Company”) (CSE:QSC; FRA:34C1) is pleased to announce the use of Glenco Medical Corp.’s (“Glenco”) Standard for Safe Sets (the “Standard”) by Pilgrim Media Group, a Lionsgate company based in North Hollywood, CA during filming of the Discovery Channel’s Shark Week special with Mike Tyson which airs starting on Sunday, August 9th at 8 pm ET on the Discovery Channel in the US. QuestCap owns a 30% equity interest in Glenco.The Standard was adopted from standards and protocols originally developed for the professional and amateur sport’s industries entitled “The Standard for Safe Sports™” prepared by Glenco. The Standard for Safe Sets is compliant with, and aligned to, the film industry’s guidelines “The Safe Way Forward” published and released in June 2020. With no end in sight for the global pandemic, world industries are just starting to restart their engines for business and commerce. “I am very active in the world of media, film and production,” said Mr. Mike Tyson, the former Heavyweight boxing champion of the world. “Entering a set today for me is a risk to me and my family, one I confidently accept with the inclusion of Glenco’s standard - a standard I know and trust,” concluded Mr. Tyson.“We were very pleased to have the protocols developed by Glenco adopted by Pilgrim Media,” stated Dr. Glenn Copeland, the CEO of Glenco and Scientific Advisor to QuestCap Inc. “It is crucial to adopt in-depth screening processes including several layers designed to assist with protocols of testing, disinfecting, reporting and responding. Our team works tirelessly to constantly develop and adapt to various industries based on strict medical and scientific data” concludes Dr. Copeland.Investor Webinar QuestCap Inc. is pleased to host a corporate webinar to provide updates and developments from investment partners.QuestCap Corporate Update Webinar QuestCap is hosting a Corporate Update webinar on Monday, August 10 at 10 am Eastern time that will give the Company’s investment partners the opportunity to provide an update on their work. Select representatives will make short presentations on their progress. Registration Link https://us02web.zoom.us/webinar/register/WN_nZtjhxAvSbej0hB06tbKRQ * Glenco Medical Corp. is a medical treatment company that specializes in extended clinical care, home treatment and innovative performance technologies using wearable, unrestricted and individual therapies to accelerate orthopaedic injury healing and training recovery. Glenco Medical shares a common interest and commitment with QuestCap in the state and well-being of public health, our communities and a safe return to normal activities for all. * Amino Therapeutics is currently focused on developing biologic therapeutics for COVID-19. Amnio’s research targets small molecule drug candidates and targeted drug delivery systems to transport biologics into the cytosol. * Spectral Analytics has received Institutional Review Board (IRB) approval for the clinical study and is the Principal Investigator for the Phase 1 study. Spectral is testing the efficacy of the combination of two FDA approved drugs to treat COVID 19.About Lionsgate Lionsgate Films (formerly known as Cinépix Film Properties) is an American film production and film distribution studio, headquartered in Santa Monica and founded in Canada, and is the flagship division of Lionsgate Entertainment. It is the largest and most successful mini-major film studio in North America. It focuses on foreign and independent films and has distributed various commercially successful film series, including The Hunger Games, Rambo, Divergent, The Punisher (prior to Marvel Studios acquiring its rights back in 2013), John Wick, Saw, Madea, Blair Witch, Now You See Me, Hostel, The Expendables, Sinister, The Twilight Saga and Step Up (both partially, via the firm's 2012 acquisition of two series' distributor Summit Entertainment. The latter was distributed by Disney's Touchstone Pictures since its first film).About QuestCap Inc. QuestCap Inc. (CSE:QSC; FRA:34C1) is a social-impact investment company. It seeks, secures and funds recognised sciences, technologies, and solutions that impact our global community today.The QuestCap executive team is complemented by a panel of global advisors that provide expertise across industries and geographies. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.QuestCap provides financing for a diverse range of entities in exchange for pre-determined royalties or distributions, or acquires all or part of one or more businesses, portfolios or other assets.For additional information, please contact:Doug Sommerville, CEO Doug.Sommerville@questcapinc.comFor US media enquires please contact: Veronica Welch veronica@vewprmedia.com +1-508-643-8000Cautionary Note Regarding Forward-looking InformationThis press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the use of the Standard; the developments made by Glenco Medical, Spectral Analytics and Amino Therapeutics; the pursuit by QuestCap of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
